1031747-40-6

Basic information

• Product Name: N-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl) cyclopropanecarboxamide
• Synonyms: N-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl) cyclopropanecarboxamide
• CAS NO: 1031747-40-6
• Molecular Weight: 287.167
• Mol File: 1031747-40-6.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: N-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl) cyclopropanecarboxamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl) cyclopropanecarboxamide(1031747-40-6)
• EPA Substance Registry System: N-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl) cyclopropanecarboxamide(1031747-40-6)

Safety Data

• Hazardous Substances Data: 1031747-40-6(Hazardous Substances Data)

Usage

Description

N-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl) cyclopropanecarboxamide is a complex chemical compound that features a cyclopropanecarboxamide group and a phenyl group, both of which are attached to a boron-containing moiety. This unique molecular structure endows the compound with distinctive chemical reactivity and coordination properties, making it a promising candidate for applications in organic synthesis, pharmaceuticals, and materials science.

Uses

Used in Organic Synthesis:
N-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl) cyclopropanecarboxamide is utilized as a synthetic intermediate for the preparation of various organic compounds. Its boron-containing structure facilitates specific types of chemical reactions, such as cross-coupling reactions, which are crucial for the synthesis of complex organic molecules.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, N-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl) cyclopropanecarboxamide serves as a building block for the development of new drugs. Its unique structure can be incorporated into drug candidates to impart desired pharmacological properties, such as improved binding affinity to target proteins or enhanced metabolic stability.
Used in Materials Science:
N-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl) cyclopropanecarboxamide is also employed in materials science for the design and synthesis of novel materials with specific properties. N-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl) cyclopropanecarboxamide's ability to participate in coordination chemistry allows it to be used in the creation of metal-organic frameworks or other advanced materials with potential applications in areas such as catalysis, sensing, or energy storage.

Upstream product

• 591-19-5 m-Bromoaniline 
• 4023-34-1 cyclopropanecarboxylic acid chloride 
• 210907-84-9 3-aminophenylboronic acid pinacolate 
• 14372-07-7 N-(3-bromophenyl)cyclopropanecarboxamide 
• 73183-34-3 bis(pinacol)diborane 

Downstream Products

• 1260151-58-3 N-methyl-N-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)cyclopropane-carboxamide 

Relevant articles and documents

Method of preparing Quinoline-5,8-dione derivatives for TGase 2 inhibitor

I Is -5,8- of the quinoline, dione derivative compound. of Formula I, or a stereoisomer or a pharmaceutically acceptable salt thereof, wherein the compound of Formula, TGase 2 has, inhibitory effects TGase 2, and thus the pharmaceutical composition may be useful for preventing or treating disorders or diseases mediated by TGase 2 or inhibiting. (by machine translation)

FUSED HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF MALARIA

A first aspect of the invention relates to a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein: R1 is -NR3R4 or -OR5; R2 is selected from aryl, heteroaryl, fused aryl- heterocycloalkyl and fused heteroaryl-heterocycloalkyl each of which may be optionally substituted by one or more R8 groups; R3 is H or alkyl; R4 is: (i) cycloalkyl optionally substituted by one or more -NR11R12, -NHCO2R11, -NHCOR11 and -NHSO2R11 groups; or (ii) -(CH2)n-heterocycloalkyl, wherein said heterocycloalkyl is a 4, 5 or 6-membered nitrogen-containing group optionally containing one or more CO groups, wherein said heterocycloalkyl is optionally substituted by one or more one or more (CH2)nR7 groups; (iii) -(CH2)n-heteroaryl, wherein said heteroaryl group is optionally substituted by one or more R7 groups; or (iv) alkyl substituted by one or more -NR11R12groups; or R3 and R4 are linked together with the nitrogen to which they are attached to form a 4, 5 or 6-membered heterocycloalkyl group optionally containing one or two further groups selected from CO, O, N and S, and which is optionally further substituted by one or more R7 groups; R5 is selected from alkyl, -(CH2)n-heteroaryl and -(CH2)n-heterocycloalkyl, wherein said heteroaryl and heterocycloalkyl groups are each optionally substituted by one or more R7 groups; each R11 and R12 is independently H or alkyl; and each n is independently an integer from O to 6; for use in treating or preventing a disorder associated with CDPK. Further aspects relate to the use of said compounds in the treatment of various therapeutic disorders, and more particularly as inhibitors of PfCDPK1.

ANTI-VIRAL COMPOUNDS

Disclosed are compounds, stereoisomers, tautomers, pharmaceutically acceptable salts, or prodrugs thereof of having Formula (I), their preparation, use, and compositions thereof for treating an infection mediated at least in part by a virus in the Flavivi